1
Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder
Condition(s):Opioid-use DisorderLast Updated:September 30, 2022Recruiting
Buprenorphine as an Intervention: 637 Clinical Trials, Page 1 of 64
Hide Studies Not Open or Pending
2
Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology
Condition(s):Opioid-use DisorderLast Updated:March 24, 2020Withdrawn
3
Open Label Comparison of Injectable Buprenorphine ( Brixadi®) and Naltrexone (Vivitrol®) for Opioid Use Disorder
Condition(s):Opioid Use DisorderLast Updated:February 3, 2023Recruiting
4
Assessing Optimal XR-Buprenorphine Initiation Points in Jail
Condition(s):Opioid Use DisorderLast Updated:March 2, 2023Not yet recruiting
5
Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
Condition(s):Neonatal Abstinence Syndrome; Neonatal Opiate Withdrawal SyndromeLast Updated:February 11, 2022Completed
6
An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder
Condition(s):Opioid-use DisorderLast Updated:March 9, 2021Completed
7
Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women
Condition(s):Opioid Use DisorderLast Updated:October 14, 2020Withdrawn
8
Fetal and Infant Effects of Maternal Buprenorphine Treatment
Condition(s):Neonatal Abstinence SyndromeLast Updated:September 26, 2017Completed
9
SUBLOCADE Rapid Initiation Study
Condition(s):Opioid-use DisorderLast Updated:October 3, 2022Completed
10
Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder
Condition(s):Moderate to Severe Opioid Use DisorderLast Updated:October 26, 2022Not yet recruiting